Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

Nasonov, E.; Fatenejad, Saeed; Feist, Eugen; Ivanova, Mariana; Korneva, Elena; Кречикова, Д. Г.; Maslyansky, A. L.; Samsonov, Mikhail; Стоилов, Румен; Зонова, Е. В.; Genovese, Mark C.

doi:10.1136/annrheumdis-2021-219876

Cited by 46 publications

(36 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Promising pre-clinical evidence led to numerous clinical trials of the anti-IL6 antibody siltuximab to treat multiple myeloma or solid tumours, but these largely reported a lack of efficacy [79,295]. Although other novel anti-IL6 antibodies are being assessed for the treatment of immune disorders [297,298] or COVID19 (NCT04348500), further work is needed to evaluate their potential against BC.…”

Section: Therapeutic Targeting Of Gp130/il6st Signallingmentioning

confidence: 99%

The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer

Martínez-Pérez

Kay

Meehan

et al. 2021

JPM

View full text Add to dashboard Cite

IL6-like cytokines are a family of regulators with a complex, pleiotropic role in both the healthy organism, where they regulate immunity and homeostasis, and in different diseases, including cancer. Here we summarise how these cytokines exert their effect through the shared signal transducer IL6ST (gp130) and we review the extensive evidence on the role that different members of this family play in breast cancer. Additionally, we discuss how the different cytokines, their related receptors and downstream effectors, as well as specific polymorphisms in these molecules, can serve as predictive or prognostic biomarkers with the potential for clinical application in breast cancer. Lastly, we also discuss how our increasing understanding of this complex signalling axis presents promising opportunities for the development or repurposing of therapeutic strategies against cancer and, specifically, breast neoplasms.

show abstract

Section: Therapeutic Targeting Of Gp130/il6st Signallingmentioning

confidence: 99%

The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer

Martínez-Pérez

Kay

Meehan

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…Siltuximab is currently studied for the treatment of COVID-19 and idiopathic multicentric Castleman disease (46)(47)(48). olokizumab is used in clinical trials for the treatment of rheumatoid arthritis with a remarkable therapeutic effect (49,50). Clazakizumab is beneficial not only for antibody-mediated rejection (51), but for active psoriatic arthritis (52).…”

Section: Discussionmentioning

confidence: 99%

Drug discovery in spinal cord injury-induced osteoporosis: a text mining-based study

Wang¹,

Xu²,

Han³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background Spinal cord injury (SCI) and osteoporosis (OP) are common diseases in spine surgery, and OP could be the complication of SCI. However, SCI-induced OP is a complex pathologic process and drug discovery is limited, which restricts the study in the mechanism and treatment of the disease. This study aims to identify the genes and molecular pathways related to SCI-induced OP through computational tools and public datasets, and to explore drug targeting therapy, ultimately preventing the occurrence of OP after SCI. Methods In this study, common genes related to SCI and OP were obtained by text mining, then which conducted the functional analysis. Protein-protein interaction (PPI) networks were constructed by STRING online and Cytoscape software. Finally, core genes and potential drugs were performed after undergoing drug-gene interaction analysis which also completed functional analysis. Results A total of 371 genes common to ‘SCI’ and ‘OP’ were identified by text mining. After functional analysis, 207 significant genes were screened out. Subsequently, PPI analysis yielded 23 genes targetable by 13 drugs which were the candidate to treat SCI-induced OP. Conclusions Taken together, siltuximab, olokizumab, clazakizumab and BAN2401 were first discovered to become the potential drugs for the treatment of SCI-induced OP. Drug discovery using text mining and pathway analysis is a significant way to investigate the pathomechanism of the disease while exploring existing drugs to treat the disease.

show abstract

“…Olokizumab (OKZ) is an IL-6 monoclonal antibody that can directly bind to IL-6 at specific sites. The results showed that there were significant differences in all secondary efficacy endpoints between the OKZ group and the placebo group, and more patients in the OKZ group reported adverse events (AEs), of which infection was the most common [36]. In conclusion, OKZ has more significance in the treatment of RA and has a high therapeutic potential value.…”

Section: Monoclonal Antibody Therapy Targeting Cytokinesmentioning

confidence: 92%

Trends of Treatment Development in Rheumatoid Arthritis: Promise, Progress, and Challenges

Jiang¹,

Wei²,

Zhao³

et al. 2022

Preprint

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic, systemic, abnormal inflammatory immune response. It is characterized by the involvement of the synovium and multiple organs and the destruction of joints and articular cartilage. In the past 30 years, several promising novel compounds and antibodies have been developed for the treatment of RA. The introduction of new drugs and precision medicine for all forms of RA raises several issues related to access to novel treatments by patients, optical regimen selection, cost-effectiveness, prognosis monitoring and outcome surveillance, particularly with regard to the development of low drug response rates, drug resistance and adverse side effects. Tremendous attention has been given to the identification of optimized drug combinations for the treatment of RA, particularly in early high-risk vulnerable and early individuals. Addressing these issues requires novel therapeutic approaches with new mechanisms and the establishment of accurate guidelines for drug selection, drug recombination, and non-chemical therapeutic efforts. In this study, we reviewed the most exciting recently established or ongoing novel drugs and approaches according to the clinical trial database maintained by the United States National Library of Medicine and discussed the trends in RA drug development and challenges in the treatment, providing a reference significant for the accurate treatment of RA and the research direction in the future.

show abstract

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

Cited by 46 publications

References 28 publications

The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer

The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer

Drug discovery in spinal cord injury-induced osteoporosis: a text mining-based study

Trends of Treatment Development in Rheumatoid Arthritis: Promise, Progress, and Challenges

Contact Info

Product

Resources

About